ArticleJournal of medical biochemistry2025
Diagnostic value of HMGB-1 and acetylcholinesterase in assessing the prognosis of patients with acute pancreatitis.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell death and its interaction with mitochondrial dysfunction in pathogenesis of acute pancreatitis: a comprehensive review.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute pancreatitis (AP) is a disorder of tissue digestion caused by abnormal activation of pancreatic enzymes, which may lead to multi-organ failure and, ultimately, death as the disease progresses. How to quickly and accurately evaluate the progression of AP has always been a hotspot and difficulty in clinical research. Methods: Sixty-four AP patients were admitted to our hospital between August 2022 and June 2023, and 60 healthy people during the same period were selected for retrospective analysis, with AP patients as the observation group and healthy people as the control group. HMGB-1 and AChE levels were detected in both groups, and the diagnostic value of HMGB-1 and AChE for AP was analysed using the receiver operating characteristic (ROC) curve. Subsequently, the differences in the expression of HMGB-1 and AChE in AP patients with different severities were further observed. In addition, we detected albumin (ALB), transferrin (TRF), and total protein (TP) in the observation group and analysed their correlation with HMGB-1 and AChE. Finally, a 6-month prognostic follow-up was performed to analyse the predictive value of HMGB-1 and AChE for poor prognosis in AP using ROC curves. Results: Compared with the control group, HMGB-1 was higher in the observation group, which was positively correlated with the severity of AP (P<0.05), while AChE was lower, which was negatively correlated with the severity of AP (P<0.05). HMGB-1+AChE had a sensitivity of 48.44% and a specificity of 88.33% for diagnosing AP (P<0.05, cut-off>0.639). In addition, HMGB-1 and nutrient proteins were positively correlated, and AChE and nutrient proteins were negatively correlated in the observation group (P<0.05). The prognostic follow-up showed that the diagnostic sensitivity of HMGB-1+AChE for poor prognosis of AP was 95.65%, and the specificity was 65.85% (P<0.05). Conclusions: HMGB-1 was elevated in AP, and AChE was decreased in AP, both of which have excellent diagnostic effects on the occurrence and poor prognosis of AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.